FDA Approved: DATSCAN — Supplemental Application (Medi-Physics Inc. dba GE Healthcare.)

View source ↗

Summary

FDA approved a supplemental application for DATSCAN (IOFLUPANE I-123), a brain imaging agent used with SPECT to evaluate suspected parkinsonian syndromes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dementia with Lewy Bodies
• Multiple System Atrophy
• Parkinson Disease

Drugs mentioned

• DaTscan (ioflupane)

Snippet

SUPPL AP for DATSCAN (IOFLUPANE I-123)